List of mAb against HLA class I–specific NK receptors evaluated in this study
| Clone . | Source* . | Isotype . | Specificity . |
|---|---|---|---|
| 11PB6 | Our laboratory, Miltenyi Biotec | IgG1 | KIR2DL1/S1 |
| EB6B | Our laboratory, Beckman Coulter | IgG1 | KIR2DL1/S1 |
| #143211 | R&D Systems | IgG1 | KIR2DL1 |
| HP-3E4 | M. Lopez-Botet, BD Pharmingen | IgM | KIR2DL1/S1/S4 |
| GL-183 | Our laboratory, Beckman Coulter | IgG1 | KIR2DL2/L3/S2 |
| CH-L | S. Ferrini, BD Pharmingen | IgG2b | KIR2DL2/L3/S2 |
| ECM-41 | Our laboratory | IgM | KIR2DL3 |
| Z27 | Our laboratory, Beckman Coulter | IgG1 | KIR3DL1/S1 |
| DX9 | Miltenyi Biotec | IgG1 | KIR3DL1 |
| AZ158 | S. Parolini | IgG2a | KIR3DL1/L2/S1 |
| Q66 | Our laboratory | IgM | KIR3DL2 |
| Z199 | Our laboratory, Beckman Coulter | IgG2b | NKG2A |
| Z270 | Our laboratory | IgG1 | NKG2A |
| #1381 | R&D Systems | IgG2b | NKG2C |
| Y9 | Our laboratory | IgM | CD94 |
| FES172 | Our laboratory, Beckman Coulter | IgG2a | KIR2DS4 |
| Clone . | Source* . | Isotype . | Specificity . |
|---|---|---|---|
| 11PB6 | Our laboratory, Miltenyi Biotec | IgG1 | KIR2DL1/S1 |
| EB6B | Our laboratory, Beckman Coulter | IgG1 | KIR2DL1/S1 |
| #143211 | R&D Systems | IgG1 | KIR2DL1 |
| HP-3E4 | M. Lopez-Botet, BD Pharmingen | IgM | KIR2DL1/S1/S4 |
| GL-183 | Our laboratory, Beckman Coulter | IgG1 | KIR2DL2/L3/S2 |
| CH-L | S. Ferrini, BD Pharmingen | IgG2b | KIR2DL2/L3/S2 |
| ECM-41 | Our laboratory | IgM | KIR2DL3 |
| Z27 | Our laboratory, Beckman Coulter | IgG1 | KIR3DL1/S1 |
| DX9 | Miltenyi Biotec | IgG1 | KIR3DL1 |
| AZ158 | S. Parolini | IgG2a | KIR3DL1/L2/S1 |
| Q66 | Our laboratory | IgM | KIR3DL2 |
| Z199 | Our laboratory, Beckman Coulter | IgG2b | NKG2A |
| Z270 | Our laboratory | IgG1 | NKG2A |
| #1381 | R&D Systems | IgG2b | NKG2C |
| Y9 | Our laboratory | IgM | CD94 |
| FES172 | Our laboratory, Beckman Coulter | IgG2a | KIR2DS4 |
Miltenyi Biotec (Bergish Gladbach, Germany); Beckman Coulter (Marseille, France); BD Pharmingen (San Diego, CA.); R&D Systems (Minneapolis, MN); Dr M. Lopez-Botet (IMIM-Hospital del Mar, Barcelona, Spain); Dr S. Ferrini (Istituto Scientifico Tumori, Genova, Italy); Dr S. Parolini (University of Brescia, Brescia, Italy).